Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.

PHAR

Pharming Group NV (PHAR)

Pharming Group NV
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:PHAR
FechaHoraFuenteTítuloSímboloCompañía
15/05/202410:52Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHARPharming Group NV
24/08/202301:00PR Newswire (US)Pharming Group to participate in September investor conferencesNASDAQ:PHARPharming Group NV
14/08/202300:00PR Newswire (US)Pharming Group to convene Extraordinary General Meeting of ShareholdersNASDAQ:PHARPharming Group NV
09/08/202300:00PR Newswire (US)Pharming announces first patient enrolled in Phase III clinical trial of leniolisib for the treatment of APDS in JapanNASDAQ:PHARPharming Group NV
03/08/202300:00PR Newswire (US)Pharming Group reports second quarter and first half 2023 financial resultsNASDAQ:PHARPharming Group NV
18/07/202300:00PR Newswire (US)Pharming to nominate industry leader Dr. Richard Peters as new Chairman of the BoardNASDAQ:PHARPharming Group NV
13/07/202301:00PR Newswire (US)Pharming Group to report second quarter and first half 2023 financial results on August 3NASDAQ:PHARPharming Group NV
01/06/202305:15Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:PHARPharming Group NV
01/06/202300:00PR Newswire (US)Pharming announces sale of priority review voucherNASDAQ:PHARPharming Group NV
25/05/202301:00PR Newswire (US)Pharming Group to attend the following Investor Conferences in JuneNASDAQ:PHARPharming Group NV
17/05/202310:28PR Newswire (US)Pharming Group reports on results of the 2023 Annual General Meeting of ShareholdersNASDAQ:PHARPharming Group NV
11/05/202300:00PR Newswire (US)Pharming Group reports financial results for the first quarter of 2023NASDAQ:PHARPharming Group NV
26/04/202301:00PR Newswire (US)Pharming to attend the H.C. Wainwright BioConnect Investor Conference 2023NASDAQ:PHARPharming Group NV
19/04/202301:00PR Newswire (US)Pharming to attend the Van Lanschot Kempen Life Sciences Conference 2023NASDAQ:PHARPharming Group NV
19/04/202300:36PR Newswire (US)Notice of First Quarter 2023 ResultsNASDAQ:PHARPharming Group NV
13/04/202306:11PR Newswire (US)Pharming to present at the 22nd Annual Needham Virtual Healthcare Conference 2023NASDAQ:PHARPharming Group NV
11/04/202300:00PR Newswire (US)Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.NASDAQ:PHARPharming Group NV
05/04/202305:57Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:PHARPharming Group NV
05/04/202301:00PR Newswire (US)Pharming Group convenes the Annual General Meeting of Shareholders 2023NASDAQ:PHARPharming Group NV
05/04/202300:00PR Newswire (US)Pharming Group announces the filing of its 2022 Annual Report and Form 20-FNASDAQ:PHARPharming Group NV
30/03/202309:39PR Newswire (US)Pharming to present at the Guggenheim Healthcare Talks - Genomic Medicines and Rare Disease DaysNASDAQ:PHARPharming Group NV
24/03/202318:22Dow Jones NewsADRs End Mostly Lower, Pharming Group Trades ActivelyNASDAQ:PHARPharming Group NV
24/03/202313:35PR Newswire (US)Pharming announces US FDA approval of Joenja® (leniolisib) as the first and only treatment indicated for APDSNASDAQ:PHARPharming Group NV
13/03/202304:43PR Newswire (US)Pharming Group announces that it expects to have full access today to its cash on deposit at Silicon Valley Bank Limited in light of UK Government announcementNASDAQ:PHARPharming Group NV
13/03/202303:34Dow Jones NewsPharming Expects to Have Access to $26 Million It Has on Deposit at SVB USNASDAQ:PHARPharming Group NV
13/03/202302:15PR Newswire (US)Pharming Group announces that it expects to have full access today to its cash on deposit at Silicon Valley Bank in light of US Government announcementNASDAQ:PHARPharming Group NV
12/03/202313:30PR Newswire (US)Pharming Group issues statement regarding the events surrounding Silicon Valley BankNASDAQ:PHARPharming Group NV
28/02/202300:00PR Newswire (US)Notice of Full Year 2022 financial resultsNASDAQ:PHARPharming Group NV
21/02/202300:00PR Newswire (US)Pharming announces first patient enrolled in pediatric clinical trial of leniolisibNASDAQ:PHARPharming Group NV
16/02/202300:00PR Newswire (Canada)Pharming provides update on EMA regulatory review of leniolisib for APDS in EuropeNASDAQ:PHARPharming Group NV
 Showing the most relevant articles for your search:NASDAQ:PHAR